Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

Research output: Contribution to conferencePaper

Standard Standard

Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. / Hughes, D.; Hughes, D.A.; Bodger, K. et al.
2008. Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK.

Research output: Contribution to conferencePaper

HarvardHarvard

Hughes, D, Hughes, DA, Bodger, K & Kikuchi, T 2008, 'Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.', Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK, 3/01/01.

APA

Hughes, D., Hughes, D. A., Bodger, K., & Kikuchi, T. (2008). Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK.

CBE

Hughes D, Hughes DA, Bodger K, Kikuchi T. 2008. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK.

MLA

Hughes, D. et al. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. Clinical Pharmacology Colloquium, Bangor University, Wales, UK, 03 Jan 0001, Paper, 2008.

VancouverVancouver

Hughes D, Hughes DA, Bodger K, Kikuchi T. Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.. 2008. Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK.

Author

Hughes, D. ; Hughes, D.A. ; Bodger, K. et al. / Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease. Paper presented at Clinical Pharmacology Colloquium, Bangor University, Wales, UK.

RIS

TY - CONF

T1 - Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

AU - Hughes, D.

AU - Hughes, D.A.

AU - Bodger, K.

AU - Kikuchi, T.

PY - 2008/4/1

Y1 - 2008/4/1

M3 - Paper

T2 - Clinical Pharmacology Colloquium, Bangor University, Wales, UK

Y2 - 3 January 0001

ER -